Clinical Data Inc

Clinical Data — Investor Presentation (November 2005)

20 slides from Clinical Data's investor presentation, Nov 8, 2005

  1. Slide 1: Investor Presentation October, 2005

    Investor Presentation October, 2005

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The following presentation contains certain forward-looking information about Clinical Data that are intended to be covered by the safe harbor for "forward-looking statements" provided by the

  3. Slide 3: Clinical Data: Leader in pharmacogenomics and clinical diagnostics

    Clinical Data Leader in commercializing pharmacogenomics and clinical diagnostics Strategic focus - genetics for efficient drug utilization - a multi- billion dollar opportunity

  4. Slide 4: Investment Highlights

    Investment Highlights Market leader in commercializing pharmacogenomics to pharma/biotech Late stage proprietary pharmacogenomic product pipeline targeting clinical marketplace Business strategy provides sustainability with significant upside potential World-wide revenues approximately $90M (pro-for

  5. Slide 5: Clinical Data Historic Business

    Clinical Data Historic Business Global Sales to Physician Office Labs and Clinics of: Chemistry and Hematology analyzers Laboratory reagents and supplies Laboratory management and consulting services Consistently profitable core business $52.9 million in revenue (TTM) $ 4.3 million operating income

  6. Slide 6: Services/Laboratory Business

    Services/Laboratory Business Leading provider of GLP & research DNA/RNA analysis services CLIA regulated laboratories US/UK operations and global sales force Strong growth across multiple markets: pharmaceutical, agricultural, government and consumer Applicable to all disease areas including oncolog

  7. Slide 7: Leveraging Core Business

    Leveraging Core Business Addition of Genaissance and Icoria adds: Leading independent pharmacogenomic and metabolomic services business Cost advantages and economies of scale High margin, proprietary molecular services businesses Core businesses foundation for innovations around therapy optimization

  8. Slide 8: Regulators and Industry Support Pharmacogenomics

    Regulators and Industry Support Pharmacogenomics FDA defining the regulatory terrain: Guidance for Pharmacogenomic Data Submissions issued 2005 Builds on early examples: Herceptin, Gleevec and Erbitux Goal is to speed development of new drugs CMS, FDA and other Payors strongly supportive Growing acc

  9. Slide 9: Comprehensive Genomics Services Business

    Comprehensive Genomics Services Business Sequencing Genotyping Molecular Sciences Gene Expression/Pathway Analysis Extraction and BioBanking Research Phase Clinical Dev. Preclinical Dev. Post Launch Product Lifecycle Supports development of BioMarkers and Clinical PGx Products

  10. Slide 10: BioMarkers Change the Drug Response Paradigm

    BioMarkers Change the Drug Response Paradigm Efficacy/safety is enriched through patient selection Drug Response Number of Patients Conventional Drugs PGx/Rx Products

  11. Slide 11: Product Pipeline: TPMT Test for Drug Toxicity

    TPMT Test for Drug Toxicity Marketed Marketed Goal: Apply to a Partner's Drug Drug-Induced Long QT Test In Development Test Marketed Expand sales PGx/Rx Depression Combination Initiate Phase II Plan PGx/Rx trial Product Pipeline 2005 2006 Partner Commence Commercialization Clozapine PGx Validation s

  12. Slide 12: Proprietary Molecular Test: Cardiac Channelopathies

    Proprietary Molecular Test Inherited disorders caused by mutations in ion channel genes: Long QT Syndrome Brugada Syndrome Arrhythmias in seemingly healthy and young individuals: Sudden cardiac death About 100,000 carriers in U.S. Cardiac Channelopathies:

  13. Slide 13: Proprietary Molecular Test

    Proprietary Molecular Test CLIA compliant test launched May 2004 Initial focus: 300 pediatric cardiologists/electrophysiologists in U.S. Internal sales force Leverage ten years of data and existing need Guides treatment options and provides clarity for other family members Over 150 patient referrals

  14. Slide 14: Drug-Induced Long QT Test

    Drug-Induced Long QT Test Major problem for pharma: >50 approved drugs prolong QT interval Major drugs (e.g., Seldane, Propulsid) withdrawn due to QT prolongation Clinical Data strategy: Use the FAMILION(tm) Test for clinical trials Use our HAP(tm)-Based Drug Response Engine to expand into drug-indu

  15. Slide 15: CARING: Expanding Clozapine for Schizophrenia

    CARING: Expanding Clozapine for Schizophrenia Clinical issues Gold standard but requires regular monitoring Objective PGx/Rx combination prospectively identifies patients likely to develop life- threatening adverse effects Progress to date Case control study DNA samples from 70 patients collected Po

  16. Slide 16: Vilazodone

    Vilazodone Primary Indication: Treatment of depression PGx/Rx Profile: PGx: Qualification of SSRI/5HT1A responders through proprietary PGx Rx: New generation dual serotonergic antidepressant Mechanism of Action: RX: A unique molecule, both a Selective Serotonin Reuptake Inhibitor (SSRI) and a 5HT1A

  17. Slide 17: Major Relationships - Services Collaborations/I.P.

    Major Relationships - Services Collaborations/I.P.

  18. Slide 18: Upcoming Milestones

    Upcoming Milestones Complete recruitment of senior management team Focus Genomic Services Business Expand adoption of the FAMILION(tm) Test Launch of Clozapine molecular test - Mid 2006 Commence Phase II clinical trial for vilazodone in H1 2006 Expand proprietary test pipeline Additional industry-le

  19. Slide 19: Investment Highlights: In Summary

    Investment Highlights Market leader in commercializing pharmacogenomics to pharma/biotech Late stage proprietary pharmacogenomic product pipeline targeting clinical marketplace Business strategy provides sustainability with significant upside potential World-wide revenues approximately $90M (pro-for

  20. Slide 20: Clinical Data

    Clinical Data‘ Investor Presentation

Clinical Data — Investor Presentation (November 2005) on 6ix